Dextromethorphan as a Potentially Safer Treatment for Agitation Associated With Dementia Due to Alzheimer's Disease
Journal of Psychosocial Nursing and Mental Health Services November 1, 2026 DOI: 10.3928/02793695-20260921-01 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | Dextromethorphan–bupropion (Auvelity) |
| Key points | Argues that sedatives and antipsychotics used for agitation in Alzheimer's disease dementia can worsen cognitive functioning, safety, and quality of life, and presents dextromethorphan–bupropion (Auvelity), repurposed by the FDA in 2026 for this indication, as an apparently safe and effective alternative. |
Abstract
Agitation associated with dementia due to Alzheimer's disease can present safety issues for older adults, potentially leading to dangerous or harmful behaviors and escalating emotional distress. The burden of persistent or severe agitation on caregivers is one of the primary reasons for hospitalization or institutionalization of persons living with dementia. Treating agitation with sedatives or antipsychotics can further reduce cognitive functioning, safety, and quality of life. The combination antidepressant drug dextromethorphan–bupropion (Auvelity) was repurposed by the U.S. Food and Drug Administration in 2026 for treatment of agitation in dementia due to Alzheimer's disease, and appears to be a safe and effective alternative.